The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil

被引:22
|
作者
Schayek, Hagit [1 ]
De Marco, Luiz [2 ]
Starinsky-Elbaz, Sigal [1 ]
Rossette, Mariana [2 ]
Laitman, Yael [1 ]
Bastos-Rodrigues, Luciana [3 ]
da Silva Filho, Agnaldo Lopes [4 ]
Friedman, Eitan [1 ,5 ]
机构
[1] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, IL-52621 Tel Hashomer, Israel
[2] Univ Fed Minas Gerais, Dept Surg, BR-30130100 Belo Horizonte, MG, Brazil
[3] Univ Fed Juiz Fora, Dept Basic Sci, BR-35010177 Governador Valadares, MG, Brazil
[4] Univ Fed Minas Gerais, Dept Gynecol & Obstet, BR-30130100 Belo Horizonte, MG, Brazil
[5] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
Population screening; recurring BRCA mutations; TP53 founder mutation; consecutive ovarian cancer cases; high risk families; HEREDITARY BREAST-CANCER; RISK-ASSESSMENT;
D O I
10.1016/j.cancergen.2015.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Brazil, several recurring mutations in BRCA1 and BRCA2 and a TP53 mutation (R337H) have been reported in high risk breast cancer cases. We hypothesized that these recurring mutations may also be detected in the general population and ovarian cancer cases in the state of Minas Gerais. To test this notion, participants were recruited from the outpatient and the Gynecological clinic in the UFMG Medical Center in Belo Horizonte, Minas Gerais, Brazil. BRCA1 (c.68_69delAG, c.5266dupC, c.181T>G, c.4034delA, c.5123C>A), BRCA2 (c.5946deIT, c.8537_8538delAG, 4936_4939delGAAA), the c.156_157insAlu* BRCA2 and the c.1010G>A *TP53 mutation were genotyped using validated techniques. Overall, 513 cancer free participants (273 men) (mean age 47.7 +/- 15.1 years) and 103 ovarian cancer cases (mean age at diagnosis 58.7 +/- 9.6 years) were studied. None of the participants were found to carry any of the genotyped mutations. We conclude that the recurring mutations in BRCA1, BRCA2 and TP53 cannot be detected in the general population or consecutive ovarian cancer cases in this geographical region in Brazil.
引用
收藏
页码:50 / 52
页数:3
相关论文
共 50 条
  • [21] BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer
    Richau, Caroline Stahnke
    Scherer, Nicole de Miranda
    Matta, Bruna Palma
    de Armas, Elvismary Molina
    Moreira, Fabio Carvalho de Barros
    Bergmann, Anke
    Chaves, Claudia Bessa Pereira
    Boroni, Mariana
    dos Santos, Anna Claudia Evangelista
    Moreira, Miguel Angelo Martins
    CANCER MEDICINE, 2024, 13 (03):
  • [22] BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
    Lalloo, F
    Varley, J
    Moran, A
    Ellis, D
    O'Dair, L
    Pharoah, P
    Antoniou, A
    Hartley, R
    Shenton, A
    Seal, S
    Bulman, B
    Howell, A
    Evans, DGR
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1143 - 1150
  • [23] Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families
    Suzanna L. Arcand
    Christine M. Maugard
    Parviz Ghadirian
    André Robidoux
    Chantal Perret
    Phil Zhang
    Eve Fafard
    Anne-Marie Mes-Masson
    William D. Foulkes
    Diane Provencher
    Steven A. Narod
    Patricia N. Tonin
    Breast Cancer Research and Treatment, 2008, 108 : 399 - 408
  • [24] Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Hyman, David M.
    Spriggs, David R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 408 - 410
  • [25] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [26] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [27] TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations:: Distinctive spectrum and structural distribution
    Greenblatt, MS
    Chappuis, PO
    Bond, JP
    Hamel, N
    Foulkes, WD
    CANCER RESEARCH, 2001, 61 (10) : 4092 - 4097
  • [28] BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients
    Laura Sarantaus
    Pia Vahteristo
    Elizabeth Bloom
    Anitta Tamminen
    Leila Unkila-Kallio
    Ralf Butzow
    Heli Nevanlinna
    European Journal of Human Genetics, 2001, 9 : 424 - 430
  • [29] BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients
    Sarantaus, L
    Vahteristo, P
    Bloom, E
    Tamminen, A
    Unkila-Kallio, L
    Butzow, R
    Nevanlinna, H
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2001, 9 (06) : 424 - 430
  • [30] Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
    Kalachand, Roshni D.
    O'Riain, Ciaran
    Toomey, Sinead
    Carr, Aoife
    Timms, Kirsten M.
    O'Toole, Sharon
    Madden, Stephen
    Bates, Mark
    O'Leary, John J.
    Gleeson, Noreen
    O'Donnell, Dearbhaile
    Grogan, Liam
    Breathnach, Oscar
    Farrelly, Angela
    Stordal, Britta
    Hennessy, Bryan T.
    OBSTETRICS & GYNECOLOGY SCIENCE, 2020, 63 (05) : 643 - 654